Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $317 million, representing a 26% increase year-over-year [9] - Non-GAAP operating income reached a record $47.5 million, up from $32.2 million in Q3 2024, with an operating margin of 15% [10] - Net income was a record $61.9 million, compared to $45 million in Q3 2024, with diluted net income per share at $1.16 [10] - Gross margin for Q3 was 90%, with expectations for medium to long-term gross margin in the high 80s range [9][10] - Adjusted free cash flow for Q3 was $92.3 million, with an adjusted free cash flow margin of 29% [11] Business Line Data and Key Metrics Changes - New products accounted for over 10% of total ARR, surpassing the 2025 goal ahead of schedule [6] - The new AI-powered Monday Campaigns product saw rapid adoption since its launch in September [7] - Monday Vibe has led to the creation of over 60,000 apps, indicating strong customer engagement [7] Market Data and Key Metrics Changes - The company reported robust net additions of over 100,000 paying customers, totaling over 500,000 [4] - The overall net dollar retention (NDR) was 111% in Q3, with expectations to remain stable for fiscal year 2025 [9] Company Strategy and Development Direction - The company is focused on transitioning to a multi-product and AI-powered platform, aiming for a revenue target of $1.8 billion by FY2027 [4][5] - Investments are being rebalanced towards mid-funnel channels to target larger opportunities, despite longer sales cycles [6] - The introduction of product bundles aims to provide a unified experience and accelerate cross-sell momentum [6][39] Management's Comments on Operating Environment and Future Outlook - Management noted healthy demand across all customer segments, particularly for AI features and products [18] - The company is optimistic about the future, citing strong customer engagement and a healthy pipeline heading into 2026 [5][20] - There is confidence in achieving the $1.8 billion revenue target for FY2027, supported by trends in customer expansion and product adoption [75] Other Important Information - The company ended Q3 with $1.53 billion in cash and cash equivalents, down from $1.59 billion at the end of Q2 [11] - Employee headcount increased to 3,018, with expectations for a 30% growth in fiscal year 2025 [10] Q&A Session Summary Question: Customer spending priorities for 2026 - Management observed a transition in customer demand across all segments, with increased interest in AI features and products [17] Question: Impact of go-to-market transition on results - The transition towards larger deals is yielding higher quality pipelines, although it comes with longer sales cycles [19] Question: Dynamics of deferred revenue - Management clarified that deferred revenue is not a perfect measurement due to cash basis accounting, and RPO is a better metric for future growth visibility [26] Question: Guidance for 2026 - Initial expectations for fiscal year 2026 will be provided in the next quarter, with confidence in achieving the $1.8 billion target by FY2027 [27][75] Question: Investment focus for 2026 - The company plans to moderate headcount growth and focus investments on sales, product, and R&D [34] Question: Adoption of AI products - Early traction has been noted for AI offerings, with significant customer engagement and use cases emerging [56][59] Question: Performance marketing channel dynamics - Management reported stabilization in new sign-ups and top-of-funnel activity, with a shift towards higher ROI channels [65] Question: RPO metric adjustments - Adjustments to the RPO metric were made for consistency and accuracy following auditor reviews [86]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $3.7 million, an increase from $2.3 million in Q3 2024, resulting in a $1.5 million increase in license revenues and a slight decrease in collaboration revenues [17] - Research and development expenses rose to $34.4 million in Q3 2025 from $30.6 million in Q3 2024, driven by a $10.1 million increase in direct R&D expenses, primarily for BLA submission preparation [18] - Selling, general, and administrative expenses increased to $19.4 million in Q3 2025 from $11.6 million in Q3 2024, mainly due to higher employee-related expenses and professional fees [18] - Cash, cash equivalents, and investment securities totaled $649.2 million as of September 30, 2025, up from $376.5 million at the end of 2024, primarily due to net proceeds from public offerings [19] Business Line Data and Key Metrics Changes - AMT-130 for Huntington's disease showed a statistically significant 75% slowing of disease progression at three years compared to an external control, meeting the pivotal study's primary endpoint [9] - AMT-260 for mesial temporal lobe epilepsy has activated 17 recruiting sites in the U.S. and completed enrollment of the first three patients in the first cohort, with updated data expected in the first half of 2026 [11] - AMT-191 for Fabry disease demonstrated supra-physiological alpha-galA enzyme activity in treated patients, with all successfully withdrawn from enzyme replacement therapy [12] Market Data and Key Metrics Changes - The company is focusing on building a foundational strategy for the U.S. market for AMT-130 while also exploring potential markets in the European Union and the United Kingdom [16] Company Strategy and Development Direction - The company remains committed to working with the FDA to clarify next steps for AMT-130 and is also planning discussions with other regulatory agencies [20] - The management emphasizes the importance of stakeholder engagement and education to prepare for a potential launch of AMT-130 [15] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment regarding the FDA's feedback on the BLA submission for AMT-130 but remains confident in the data and its potential to benefit patients [5][10] - The company plans to engage urgently with the FDA to discuss the next steps and remains committed to transparency and collaboration [6][11] Other Important Information - Enrollment in the phase I-II trial of AMT-162 for SOD1 ALS has been paused due to safety concerns, with ongoing data collection from treated patients [13] Q&A Session Summary Question: Treatment effect and external control arm construction - The company conducted rigorous propensity score matching with Enroll-HD and performed various sensitivity analyses to ensure robustness of findings [27] Question: Details on AMT-162 and dose differences - The middle dose of AMT-162 was about three-fold higher than the low dose, and the company is monitoring data to determine next steps [31] Question: Expectations from final meeting minutes with the FDA - The company hopes the minutes will outline FDA concerns and provide guidance on addressing those in future meetings [34] Question: Confirmation of prior meeting minutes regarding accelerated approval - The company confirmed that previous meetings indicated the data could support a BLA submission and that the composite UHDRS was an acceptable endpoint [37] Question: Future investment in Huntington's program - The company is committed to collaborating with the FDA to find an expedited path for BLA submission, emphasizing the urgency of patient needs [41] Question: EMA or MHRA feedback on AMT-130 - The company has not yet engaged with EMA or MHRA but plans to prioritize discussions with the FDA first [47]

Financial Data and Key Metrics Changes - Pagaya achieved consistent GAAP net income profitability, with an exit rate of over $120 million on an annual basis [5] - Network volume grew 19% year over year to a record $2.8 billion, with a 31% growth in personal loans [21] - Total revenue and other income rose 36% to a record $350 million, driven by fee revenue growth outpacing volume [21] - Adjusted EBITDA increased 91% to a record $107 million, with margins expanding 9 percentage points to 30.6% [22] - GAAP net income of $23 million represented a significant improvement from a net loss of $67 million in Q3 2024 [23] Business Line Data and Key Metrics Changes - Personal loans accounted for a significant portion of growth, with cumulative net losses trending approximately 35%-40% lower than peak levels in Q4 2021 [27] - Point of Sale (POS) volumes grew to about $1.4 billion, up from $1.2 billion last quarter [19] - Auto annualized volumes increased to $2.2 billion, up from $2 billion last quarter [19] - Multi-product partners represent only 30% of Pagaya's partners by number but contribute more than two-thirds of the volume [16] Market Data and Key Metrics Changes - Pagaya issued $1.8 billion in ABS programs across four transactions during the third quarter [29] - The company raised $500 million in corporate debt and expanded its corporate revolver with four new major banks [9] - The demand for Pagaya's assets remained consistent and robust, with strong investor interest across all asset classes [25] Company Strategy and Development Direction - The company is focusing on product-led growth and enhancing its product offerings to solve fundamental challenges facing lenders and consumers [6] - Pagaya aims to become a necessary utility for every lender in the U.S. by deepening partner engagement and expanding its funding network [8] - The strategy includes institutionalizing relationships with lending partners through long-term agreements and product agreements [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate through economic cycles, emphasizing a disciplined approach to underwriting and risk management [20] - The macroeconomic environment remains stable, with no significant deterioration in credit performance observed [56] - The company expects to maintain steady growth in personal loans and continued expansion in auto and POS products [32] Other Important Information - Pagaya introduced a new reporting line for Gains and Losses on Investments in Loans and Securities to enhance transparency [23] - The company ended the quarter with $265 million in cash and cash equivalents and $888 million in investments in loans and securities [30] Q&A Session Summary Question: Can you provide perspective on credit quality and borrowers' ability to manage their credits? - Management stated that credit performance is well within expectations, reflecting a balanced and conservative underwriting approach [34][35] Question: How has risk retention changed with successful ABS issuances? - The company noted robust demand for origination and a diversified funding strategy, with a current mix of approximately 60-40% between ABS and other structures [41] Question: Can you discuss the differences between Pagaya's B2B model and traditional B2C lenders? - Management highlighted that Pagaya's B2B model allows for more stable growth without the fluctuations associated with B2C marketing spend [44][49] Question: What is the outlook for potential new asset classes? - Management indicated that home improvement credit is gaining traction, but any expansion will be approached with strict criteria to ensure market stability and partner interest [60][63]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $7.6 million compared to a net loss of $7.7 million in the prior year quarter, attributed to the timing of revenue recognized under the collaboration agreement with GSK [22] - Research and development expenses increased to $45.9 million from $41.2 million year-over-year, driven by advancements in the inhibin E and RNA editing programs [22] - General and administrative expenses rose to $18.1 million from $15 million in the prior year quarter, primarily due to share-based compensation [22] - Net loss for Q3 2025 was $53.9 million, an improvement from a net loss of $61.8 million in the prior year quarter [23] - Cash and cash equivalents at the end of Q3 2025 were $196.2 million, down from $302.1 million as of December 31, 2024, but extended cash runway into Q2 2027 with additional proceeds [24] Business Line Data and Key Metrics Changes - The company highlighted significant advancements in the WVE-007 program, showing dose-dependent reductions in activin E levels, with reductions of 56%, 75%, and 85% for different dosing cohorts [8][9] - WVE-006 demonstrated the potential to restore physiological AAT production, achieving AAT levels of up to 13 micromolar and a 60% decrease in mutant ZAAT protein [13] - The DMD program, WVEN531, showed a statistically significant improvement in time to rise, with a 3.8 seconds improvement compared to natural history [18] Market Data and Key Metrics Changes - The company is addressing a significant market need with an estimated 9 million homozygous individuals living with PNPLA3I148M liver disease in the US and Europe, who are at a nine-fold higher risk of dying from their liver disease compared to non-carriers [16] - The obesity market is highlighted as having over 1 billion individuals living with obesity, many of whom lack access to current GLP-1 therapies, presenting a unique opportunity for the company's treatments [55] Company Strategy and Development Direction - The company is focused on advancing its pipeline, particularly in RNAi and RNA editing, with a strategy to leverage proprietary chemistry and platform innovations [5] - There is a strong emphasis on developing non-incretin treatment approaches for obesity, with WVE-007 positioned as a potential maintenance therapy to prevent rebound weight gain [6][11] - The company aims to build on its momentum in the obesity space, with plans for further studies and potential partnerships to enhance development [43] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress made in clinical trials, particularly with WVE-007 and WVE-006, and the potential for these therapies to transform treatment paradigms [25] - The management team acknowledged the competitive landscape in the obesity market and the need for innovative solutions that provide durable results without the side effects associated with current therapies [55] - There is confidence in the ability to meet regulatory requirements and achieve clinical milestones, with ongoing discussions with the FDA regarding imaging endpoints for Huntington's disease [29][30] Other Important Information - The company is preparing for a global potentially registrational phase 2-3 study of WVE-003 in adults with Huntington's disease, using caudate volume as a primary endpoint [19] - The company has received positive feedback from key opinion leaders regarding the potential of its RNA editing programs to address unmet medical needs [14] Q&A Session Summary Question: Inquiry about cholesterol fat mobilization post-inhibin knockdown - Management confirmed no observed changes in increased lipids and deposits in the liver from preclinical studies, indicating positive findings regarding fat mobilization [26][27] Question: Pre-IND meeting with FDA regarding Huntington's imaging endpoints - Management confirmed alignment with the FDA on using MRI as an imaging endpoint, emphasizing the importance of well-designed clinical trials [29] Question: Changes in gene expression timing in obesity studies - Management noted that while gene expression changes occur over time, early engagement of targets and sustained suppression of proteins are observed [34] Question: Insights on acute phase response in AATD patient - Management indicated that the patient responded as expected, with no new insights beyond the initial findings [48] Question: Future studies beyond NYTE for obesity program - Management expressed interest in exploring further studies and potential strategic partnerships, while noting that the GSK collaboration would not hinder these opportunities [62]

Financial Data and Key Metrics Changes - Revenue from continuing operations was $14 million, down 4% year over year but up 8% sequentially, driven by strong demand for FTIR devices [4][18] - Year-to-date revenues from continuing operations totaled $38.8 million, representing a 16% increase year over year [5] - Adjusted EBITDA loss was $1.8 million for Q3, an improvement of over $5 million year over year [5][22] - The company ended the quarter with approximately $112 million in cash and marketable securities, with no debt outstanding [23] Business Line Data and Key Metrics Changes - FTIR devices accounted for 42% of revenue, with the Explorer Gas Identification device showing strong demand [4] - Recurring revenue represented 36% of total revenue, with a 10% increase year over year [5][19] - Handheld product and service revenue was $13.2 million, down 5% from the prior year [18] Market Data and Key Metrics Changes - The U.S. Coast Guard purchased 23 MX908 devices for narcotics interdiction, contributing to the installed base growth of 27% year over year [4] - International engagement and order flow remain solid, although U.S. export licensing requirements may extend delivery times [7] Company Strategy and Development Direction - The company aims to increase adoption of its devices to address global threats to public health and safety, focusing on rapid chemical identification tools [8][9] - The strategy includes expanding the handheld portfolio and increasing the share of recurring revenue to reduce dependency on large enterprise deals [26] - The company is also advancing its next-gen analytical tools portfolio, including the launch of VIPER, a handheld chemical analyzer [12][15] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about achieving full-year guidance despite potential impacts from the U.S. government shutdown [8][24] - The company expects revenue from continuing operations to be in the range of $54-$56 million for the full year, representing growth of 13%-17% over 2024 [23][24] - Management highlighted the importance of government resuming normal operations for achieving Q4 revenue expectations [30] Other Important Information - The company is on track to achieve positive adjusted EBITDA by Q4 2025, supported by revenue projections and lower operating costs [26] - The gross margin increased to 58% on an adjusted basis, reflecting improvements from operational changes [16][21] Q&A Session Summary Question: Clarification on the $4 million impact on guidance - Management confirmed that the $4 million potential impact is included in the full-year guidance and is considered a timing issue [29][30] Question: Update on AVCAD program and Coast Guard order - The Coast Guard order was included in Q3 shipments, and clarity on the AVCAD program's next steps is expected by year-end [31][32] Question: Sensitivities around adjusted EBITDA break-even - Management indicated that achieving adjusted EBITDA positivity is contingent on landing anticipated orders and maintaining revenue guidance [34][36] Question: Production capabilities and supply chain risks - Management expressed confidence in production capabilities and does not foresee significant supply chain issues affecting AVCAD fulfillment [45][46] Question: Impact of government shutdown on future revenues - Management views the shutdown as a timing issue and remains optimistic about the pipeline and future revenue recognition [47][50]

Financial Data and Key Metrics Changes - Total revenue for the second quarter was $107 million, exceeding the high end of guidance, with adjusted EBITDA at negative $1.4 million within guidance range [5][12][18] - The company is now debt-free after paying off a $45 million convertible note, strengthening its balance sheet [4][12] Business Line Data and Key Metrics Changes - The commerce segment generated $24.8 million in revenue, up 6% year over year, contributing 24% to total revenue, marking an all-time high [5][12] - BARK Air revenue reached $3.6 million, up more than 138% year over year and 54% from the prior quarter, with a 99% five-star review rate [6][12] Market Data and Key Metrics Changes - Direct-to-consumer (D2C) revenue, excluding BARK Air, was $78.5 million, down from last year due to a smaller subscriber base and moderated marketing spend [12][13] - The company experienced the lowest customer acquisition cost since fiscal 2023, with two-thirds of new subscribers opting for premium offerings [9][10] Company Strategy and Development Direction - The company is focused on revenue diversification and maintaining bottom-line discipline, with plans to expand retail distribution and product assortment [5][12] - The partnership with the Girl Scouts for their annual cookie program is expected to enhance brand awareness and revenue opportunities [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in executing the plan despite external challenges such as tariffs and macroeconomic volatility, aiming for profitability by the end of the fiscal year [22][25] - The company anticipates improved gross margins in the second half of fiscal 2026 due to strategic sourcing and price increases [14][18] Other Important Information - The company ended the quarter with $63 million in cash, down $22 million sequentially due to working capital timing [17] - Guidance for the fiscal third quarter is set at total revenue between $101 million and $104 million, with adjusted EBITDA between negative $5 million and negative $1 million [18] Q&A Session Summary Question: What flexibility does being debt-free provide? - Management indicated that being debt-free allows for continued execution of the business plan without the burden of interest payments, focusing on reinvestment for growth [20][21] Question: Confidence in achieving full-year profitability? - Management maintains the goal of being EBITDA positive by year-end, acknowledging the volatility in tariffs and consumer sentiment [25] Question: Factors driving commerce growth? - Growth in the commerce segment is attributed to increased distribution, product availability, and timing benefits from orders shifting into Q2 [26][27] Question: Insights on subscriber acquisition and retention? - Improved retention is driven by a favorable mix of organic customer acquisition and enhancements in the subscription platform, leading to higher quality subscribers [30][34][40]

Financial Data and Key Metrics Changes - As of September 30, 2025, the company had approximately $86 million in cash, cash equivalents, short-term bank deposits, and investments in marketable securities [15] - Revenues for Q3 2025 were approximately $1.9 million, a significant decrease from approximately $17.1 million in Q3 2024 [15] - R&D expenses for Q3 2025 were approximately $5.8 million, down from approximately $6.3 million in Q3 2024 [16] - G&A expenses for Q3 2025 were approximately $2.2 million, compared to approximately $2.6 million in the same period in 2024 [16] - The net loss for Q3 2025 was approximately $6.98 million, or $0.07 per share, compared to a net profit of approximately $1.28 million, or $0.01 per share in Q3 2024 [16] Business Line Data and Key Metrics Changes - The company is advancing its COM701 trial for platinum-sensitive ovarian cancer, with interim analysis now expected in Q1 2027 [12][20] - COM902 is highlighted as one of the only two clinical-stage FC-reduced anti-TIGIT monoclonal antibodies currently in development, fully owned by the company [7] - The partnership with AstraZeneca for Rilvegostomig, an FC-reduced anti-PD-1 TIGIT bispecific, is expected to generate substantial revenue, with peak year revenue targets exceeding $5 billion [8] Market Data and Key Metrics Changes - The company is positioned to capture market opportunities as new data emerges, particularly with readouts anticipated from 2026 [7] - The overall survival data from recent trials indicates a median overall survival of 27 months for FC-reduced formats, compared to benchmarks of 15 months or less [8] Company Strategy and Development Direction - The company emphasizes its focus on computational drug target discovery and digital biology, aiming to deliver significant value for patients [4] - The strategy includes five key value drivers, with a strong emphasis on FC-reduced TIGIT programs and the potential of COM902 [7] - The company is committed to delivering breakthroughs in cancer treatment, leveraging its AI/ML-powered discovery engine [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strong fundamentals and strategic direction, particularly in the context of evolving clinical data [4] - The management team highlighted the importance of safety and efficacy in their drug development approach, particularly regarding the FC-reduced formats [6] - The company anticipates that the cash runway will support operations into Q3 2027, allowing continued investment in clinical trials and early-stage pipeline development [15][20] Other Important Information - The company presented a pooled analysis of COM701 at ESMO, demonstrating its clinical benefit in heavily pretreated platinum-resistant ovarian cancer [11] - The ongoing Maya ovarian platform trial is seen as a significant opportunity to address unmet medical needs in the treatment of ovarian cancer [12] Q&A Session Summary Question: What caused the extension of the Maya interim analysis to Q1 2027? - The extension is due to factors such as site openings, enrollment rates, and the accumulation of PFS events [17][18] Question: What are the expectations for the upcoming Arcus-Gilead readout with their TIGIT in gastric cancer? - The readout is significant as it will be the first phase three readout for an FC-reduced TIGIT antibody, and its success could validate the company's hypotheses [21][22] Question: What internal thresholds are being looked for from the interim update from Maya ovarian? - The trial is exploratory, aiming to demonstrate single-agent activity, with an improvement of up to three months above placebo being clinically meaningful [25] Question: Can COM902 be partnered with another company despite the license agreement with AstraZeneca? - The company retains full ownership of COM902 and has no restrictions on pursuing partnerships, allowing for flexibility in future collaborations [27] Question: How does the tolerability profile of COM701 influence its use in combination therapies? - COM701 is well tolerated as a monotherapy, which supports its potential use in combination therapies with standard care agents [29]

Financial Data and Key Metrics Changes - Total revenue reached $21.1 million, up 62% year-over-year, marking the third consecutive quarter of acceleration [11] - Tech financing fee on supply chain loans was $15.6 million, up 51% year-over-year, driven by strong hash rate loan growth [11] - Total loans facilitated on NLPaaS Prime reached $2.4 billion, up 60% year-over-year [12] - Adjusted EBITDA margin reached 40% in Q3, compared to 14% a year ago, excluding non-recurring items [15] Business Line Data and Key Metrics Changes - Tech platform fee on margin loans doubled year-over-year to $5.5 million [11] - Average loan amount per customer for supply chain loans is approximately $32 million, while for margin loans it is roughly $47 million, both growing over 50% year-over-year [33] Market Data and Key Metrics Changes - The number of institutional clients increased by 28% year-over-year in Q3 [12] - Total value of loans (TVL) per customer on a 12-month rolling basis increased by 55% year-over-year [12] Company Strategy and Development Direction - The company is focusing on globalization and the NLPaaS RWA hub as strategic priorities for growth [6][7] - The acquisition of Prestige Wealth, renamed Aurelion, is a pivotal milestone in the company's treasury strategy, aiming to grow Aurelion to a $10 billion Tether Gold DATT over time [9][17] Management's Comments on Operating Environment and Future Outlook - Management expects revenue for Q4 to range between $26 million and $28 million, representing 94%-109% growth year-over-year [15] - The company is leveraging its platform to drive sustainable revenue growth, expand margins, and strengthen its balance sheet [15] Other Important Information - Funding costs on supply chain loans declined to 5.18%, down 29 basis points from a year ago [13] - The company is seeing new lending scenarios emerging from the large growing crypto market [5] Q&A Session Summary Question: Is the fourth quarter guidance assuming any benefit from Aurelion, or is it organically all NLPaaS? - Management clarified that they do not derive revenue from Aurelion; instead, Aurelion raises capital and lends gold to strengthen NLPaaS's balance sheet [20] Question: Can you expand on pricing power in the business? - Management noted that despite the Fed decreasing interest rates, they have been able to maintain tech fees, which has improved margins [22] Question: What is the proper range for net interest margin, and can it reach 2%? - Management indicated that net interest margin has been improving and there is potential for growth as the brand scales and trust increases [30] Question: What is the average loan amount per customer? - The average loan amount for supply chain loans is approximately $32 million, and for margin loans, it is roughly $47 million, both growing over 50% year-over-year [33] Question: Can you provide the total number of customers at quarter end in each segment? - Management stated that for supply chain loans, the number is close to 50, and for margin loans, it is a little above 40, totaling approximately 80 customers [35][36]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 reached $169.7 million, representing a 173.6% increase year-over-year and a 9.1% increase sequentially [4][17] - Gross profit was $40.8 million, with a gross margin of 24.1%, compared to 4.5% in Q3 2024 and 8.2% in Q2 2025 [17][18] - Adjusted EBITDA was positive $43 million, a significant improvement from negative $7.9 million in Q3 2024 [21] - Net loss for the quarter was $266.7 million, compared to $50.1 million in Q3 2024 [20][24] Business Line Data and Key Metrics Changes - Self-mining revenue was $130.9 million, up 315.6% year-over-year and 120.7% sequentially, driven by a 273.1% year-over-year increase in self-mining hash rate [17][21] - Seal Miner sales revenue was $11.4 million, compared to $0 in Q3 2024 and $69.5 million in Q2 2025 [17] Market Data and Key Metrics Changes - The average operating self-mining hash rate increased to 29.1 exahash per second, a 273.1% year-over-year and 105.4% sequential increase [5][17] - As of the end of October, the company achieved 41.2 exahash per second, surpassing its target of 40 exahash per second [6] Company Strategy and Development Direction - The company aims to transition from a Bitcoin mining leader to a vertically integrated Bitcoin infrastructure and AI platform [4] - Future growth will focus on three strategic pillars: Bitcoin mining, ASIC development, and HPC AI [7] - The company plans to develop data centers using its internal team and strategic hiring, moving away from a joint venture model [8][64] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued growth in self-mining and AI cloud services, anticipating significant demand in both sectors [12][78] - The supply and demand imbalance for AI compute is expected to persist well into 2027, with potential revenue exceeding $2 billion by the end of 2026 from AI cloud services [12][78] Other Important Information - The company has a total available electrical capacity of approximately 1.6 gigawatts and a global power pipeline of about 3 gigawatts [14] - The company is actively seeking low-cost power sites globally to reinforce its competitive advantage [15] Q&A Session Summary Question: What is the progression of the HPC opportunity? - Management confirmed simultaneous expansion in Malaysia and the U.S. for AI cloud services [36] Question: Are all AI services focused on NVIDIA? - Currently, all AI initiatives are largely NVIDIA-based, with no plans to develop proprietary AI chips [39] Question: What was the process for acquiring the Niles, Ohio site? - The Niles site was strategically acquired to provide long-term optionality, with energization expected in Q1 2029 [41] Question: What caused the delay in the Seal 04 miner chip? - The delay is due to the complexity of implementing new architecture and design changes [46] Question: How will the company decide between cloud service and co-location? - The primary focus is on AI cloud services, with co-location being opportunistic [54] Question: What is the expected return on invested capital for cloud services versus co-location? - The return profiles differ significantly, influenced by construction costs and end-user requirements [95]

Financial Data and Key Metrics Changes - The company reported a loss from continuing operations net of tax of $166 million for the quarter [24] - Cash and cash equivalents stood at $4.4 billion with no debt on the balance sheet, indicating a strong capital position [24][25] Business Line Data and Key Metrics Changes - The company highlighted significant progress in its late-stage pipeline, with 11 potentially registrational trials and indications with blockbuster potential [8][9] - Brepocitinib's data in dermatomyositis (DM) hit all 10 ranked endpoints, with an NDA filing planned for the first half of next year [5][10] - The Graves' disease trial for batoclimab demonstrated disease-modifying potential, with a significant portion of patients achieving remission [19][20] Market Data and Key Metrics Changes - The company noted a large patient population for Graves' disease, with approximately 880,000 diagnosed patients in the U.S., of which 330,000 are uncontrolled or intolerant to current therapies [19] - The unmet medical need in the DM landscape is significant, with 75% of patients currently on only steroids or immunosuppressive therapies [11][12] Company Strategy and Development Direction - The company is focused on expanding its pipeline and achieving profitability, with a strong emphasis on the upcoming investor day to discuss future strategies [8][25] - The management expressed excitement about the potential of their therapies in addressing significant unmet needs in various indications, including Graves' disease and DM [9][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the competitive landscape in Graves' disease and expressed confidence in their product's profile and the overall market opportunity [33][60] - The company is optimistic about the upcoming data readouts and the potential for their therapies to transform treatment paradigms in their target indications [16][78] Other Important Information - The company is involved in ongoing litigation related to LNP technology, with a jury trial in the Moderna case scheduled for March 2026 [24] - The company has a favorable marketing ruling in the Pfizer case, which is expected to progress in the near future [24] Q&A Session Summary Question: What should be watched next regarding Pfizer litigation? - Management indicated that the scheduling process for the Pfizer case is underway, and more information about the timeline, including a potential trial date, will be available soon [29] Question: Thoughts on Argenx entering the Graves' market? - Management acknowledged the competitive landscape but expressed confidence in their product's competitive profile and the overall patient population's needs [33][34] Question: What to expect from the investor day? - Management stated that the investor day will provide a comprehensive overview of the company's transformation and future opportunities, with potential new data to be shared [36][38] Question: Insights on remission data for Graves' disease? - Management emphasized that deeper IgG reductions are expected to drive remission rates and that they will learn more from ongoing studies [42][44] Question: Update on the competitive landscape in Graves' disease? - Management noted the increasing competition but expressed confidence in their FcRn mechanism's safety and efficacy, which positions them well in the market [60][62] Question: Status of the overseas study with 1402? - Management confirmed that several large registrational programs are ongoing, and they will share updates as they become available [99]